跳至主要内容
临床试验/NCT07821515
NCT07821515招募中不适用

Does Paracetamol Influence the Release of Gut Hormones, Glucose Absorption and Glycemia?

University of Copenhagen2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
12
试验地点
2
主要终点
Glucagon-like peptide 1

研究概览

简要总结

The study aim is to determine whether acute inhibition of endogenous prostaglandin synthesis by paracetamol affects the release of gut hormones, glucose absorption and glycemia in healthy young individuals

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

identical capsules containing Paracetamol and placebo is prepared by the pharmacy

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Nondiabetic fasting plasma glucose (< 7.0 mmol/L) at time of inclusion
  • BMI of 20-25
  • Written informed consent

排除标准

  • Haemoglobin < 7.9 mmol/L
  • Pregnancy or breastfeeding
  • Significant gastrointestinal symptoms (e.g. dyspepsia, postprandial pain)
  • Use of medication that cannot be paused for 12 hours or any drug that affects gastric emptying, small intestinal motility, glucose absorption.
  • Use of paracetamol, NSAID, aspirin or similar within the previous week.
  • Evidence of drug abuse, consumption of tobacco in any form or daily consumption of more than 20g alcohol
  • History of gastrointestinal disease, including significant upper or lower gastrointestinal symptoms, pancreatitis, or previous gastrointestinal surgery including cholecystectomy (but not uncomplicated appendicectomy)
  • Participation in other research studies within the previous 3 months
  • Inability to give informed consent
  • Intolerance to any of the components of paracetamol and the meals used for the study

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Other)

Paracetamol (1000mg)

Active Comparator

干预措施: Paracetamol (Other)

结局指标

主要结局

Glucagon-like peptide 1

时间窗: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min

Plasma concentration

次要结局

  • Glucose(From baseline samples (-15, 0 min) until the end of the meal test at t = 180min)
  • Gastrin(From baseline samples (-15, 0 min) until the end of the meal test at t = 180min)
  • Cholecystokinin(From baseline samples (-15, 0 min) until the end of the meal test at t = 180min)
  • Glucose-dependent insulinotropic polypeptide (GIP)(From baseline samples (-15, 0 min) until the end of the meal test at t = 180min)
  • C-peptide(From baseline samples (-15, 0 min) until the end of the meal test at t = 180min)
  • Glucagon(From baseline samples (-15, 0 min) until the end of the meal test at t = 180min)
  • Pancreatic polypeptide(From baseline samples (-15, 0 min) until the end of the meal test at t = 180min)
  • 3-OMG(From baseline samples (-15, 0 min) until the end of the meal test at t = 180min)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Simon Veedfald

Assistant professor

University of Copenhagen

研究点 (2)

Loading locations...

相似试验